These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29658945)

  • 1. [Experience with OK-432 in lymphatic vascular malformations in a hospital from northern Mexico].
    Reyes JAC; Escurra EAM; Rangel JC; Ita JR; Lindemann JL; García LFR; López BJC
    Bol Med Hosp Infant Mex; 2018; 75(2):89-93. PubMed ID: 29658945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cystic lymphatic vascular malformations with OK-432 sclerotherapy.
    Peters DA; Courtemanche DJ; Heran MKS; Ludemann JP; Prendiville JS
    Plast Reconstr Surg; 2006 Nov; 118(6):1441-1446. PubMed ID: 17051116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OK-432 and lymphatic malformations in children: the Starship Children's Hospital experience.
    Wheeler JS; Morreau P; Mahadevan M; Pease P
    ANZ J Surg; 2004 Oct; 74(10):855-8. PubMed ID: 15456432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of lymphangiomas with OK-432 (Picibanil).
    Rautio R; Keski-Nisula L; Laranne J; Laasonen E
    Cardiovasc Intervent Radiol; 2003; 26(1):31-6. PubMed ID: 12491020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of lymphatic malformations with OK-432 (Picibanil): review of the literature.
    Poldervaart MT; Breugem CC; Speleman L; Pasmans S
    J Craniofac Surg; 2009 Jul; 20(4):1159-62. PubMed ID: 19553857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic Malformation Architecture: Implications for Treatment With OK-432.
    Malic CC; Guilfoyle R; Courtemanche RJM; Arneja JS; Heran MKS; Courtemanche DJ
    J Craniofac Surg; 2017 Oct; 28(7):1721-1724. PubMed ID: 28834841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OK-432 (Picibanil) therapy for lymphangiomas in children.
    Laranne J; Keski-Nisula L; Rautio R; Rautiainen M; Airaksinen M
    Eur Arch Otorhinolaryngol; 2002 May; 259(5):274-8. PubMed ID: 12107533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial.
    Giguère CM; Bauman NM; Sato Y; Burke DK; Greinwald JH; Pransky S; Kelley P; Georgeson K; Smith RJ
    Arch Otolaryngol Head Neck Surg; 2002 Oct; 128(10):1137-44. PubMed ID: 12365884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-center experience in the management of head and neck lymphangiomas.
    Aluffi Valletti P; Brucoli M; Boffano P; Benech A; Toso A; Dell'Era V; Garzaro M
    Oral Maxillofac Surg; 2020 Mar; 24(1):109-115. PubMed ID: 31960163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of OK-432 immunotherapy of lymphatic malformations.
    Smith MC; Zimmerman MB; Burke DK; Bauman NM; Sato Y; Smith RJ;
    Laryngoscope; 2009 Jan; 119(1):107-15. PubMed ID: 19117316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Unsuccessful treatment with OK-432 picibanil for orbital lymphangioma].
    Lanuza García A; Bañón Navarro R; Llorca Cardeñosa A; Delgado Navarro C
    Arch Soc Esp Oftalmol; 2012 Jan; 87(1):17-9. PubMed ID: 22248653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of lymphatic malformations in oral and maxillofacial regions: the rationale according to the new classification].
    Zheng JW; Qin ZP; Zhang ZY
    Shanghai Kou Qiang Yi Xue; 2005 Dec; 14(6):553-6. PubMed ID: 16400476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [OK-432 therapy for lymphangioma in children].
    Ruiz E; Valera ET; Veríssimo F; Tone LG
    J Pediatr (Rio J); 2004; 80(2):154-8. PubMed ID: 15079187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerosing of recurrent lymphangioma using OK-432.
    Mikhail M; Kennedy R; Cramer B; Smith T
    J Pediatr Surg; 1995 Aug; 30(8):1159-60. PubMed ID: 7472972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with lymphatic malformations who receive the immunostimulant OK-432 experience excellent long-term outcomes.
    Ghaffarpour N; Petrini B; Svensson LA; Boman K; Wester T; Claesson G
    Acta Paediatr; 2015 Nov; 104(11):1169-73. PubMed ID: 26081020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OK-432 sclerotherapy of lymphatic malformation in the head and neck: factors related to outcome.
    Kim DW
    Pediatr Radiol; 2014 Jul; 44(7):857-62. PubMed ID: 24569928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerosing treatment of lymphangiomas with OK-432.
    Luzzatto C; Midrio P; Tchaprassian Z; Guglielmi M
    Arch Dis Child; 2000 Apr; 82(4):316-8. PubMed ID: 10735841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sclerotization of orbital lymphangioma with OK-432].
    Lagrèze W; Metzger M; Rössler J
    Ophthalmologe; 2014 May; 111(5):479-81. PubMed ID: 24706253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of lymphangiomas in children: an update of Picibanil (OK-432) sclerotherapy.
    Greinwald JH; Burke DK; Sato Y; Poust RI; Kimura K; Bauman NM; Smith RJ
    Otolaryngol Head Neck Surg; 1999 Oct; 121(4):381-7. PubMed ID: 10504592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of OK-432 sclerotherapy in treatment of lymphatic malformations: long-term follow-up results.
    Weitz-Tuoretmaa A; Rautio R; Valkila J; Keski-Säntti H; Keski-Nisula L; Laranne J
    Eur Arch Otorhinolaryngol; 2014 Feb; 271(2):385-90. PubMed ID: 23649509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.